Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.68 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.54 |
| ▸ | FEN1 | P39748 | 1/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7008751 | 0.81 | DAO (1.00) | DAOERCC5FEN1TSHRLMNA | |
| SCHEMBL13295221 | 0.79 | LMNA (0.68) | DAOERCC5FEN1TSHRLMNA | |
| SCHEMBL12321245 | 0.79 | YEATS4 (0.54) | DAOERCC5FEN1F2TSHR | |
| SCHEMBL3060952 | 0.79 | DAO (0.68) | DAOERCC5FEN1F2TSHR | |
| SCHEMBL6616036 | 0.78 | TSHR (0.50) | DAOERCC5FEN1F2TSHR | |
| SCHEMBL7371767 | 0.77 | F2 (0.46) | DAOERCC5FEN1F2TSHR | |
| SCHEMBL6181512 | 0.77 | F2 (0.71) | DAOF2TSHRIKBKBRAB9A | |
| SCHEMBL24198720 | 0.76 | DAO (0.63) | DAOERCC5FEN1TSHRLMNA | |
| SCHEMBL6677272 | 0.76 | DAO (0.89) | DAOERCC5FEN1TSHRLMNA | |
| SCHEMBL27244010 | 0.76 | DAO (0.63) | DAOERCC5FEN1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023109926-A1 | SPIROOXINDOLE COMPOUND AND USE THEREOF IN PREPARATION OF PROTEASE INHIBITOR AS ANTIVIRAL DRUG | 南京药石科技股份有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-20220249447-A1 | CF3-, OCF3-, SCF3-, and SF5-Containing Antibacterial Agents | PURDUE RESEARCH FOUNDATION | 2022-08-11 | — | — | US | disclosed |
| EP-3958679-A1 | CF3-, OCF3-, SCF3- AND SF5-CONTAINING ANTIBACTERIAL AGENTS | Purdue Research Foundation (US) | 2022-03-02 | — | — | EP | disclosed |
| US-20170202849-A1 | ANTIPARASITIC COMPOUNDS | AVISTA PHARMA SOLUTIONS, INC. | 2017-07-20 | — | — | US | disclosed |
| US-9643963-B2 | Antiparasitic compounds | AVISTA PHARMA SOLUTIONS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160280700-A1 | ANTIPARASITIC COMPOUNDS | SNAPDRAGON CHEMISTRY, INC. | 2016-09-29 | — | — | US | disclosed |
| US-6380218-B1 | FOR THERAPY OF RESPIRATORY, ALLERGIC, AND INFLAMMATORY DISORDERS COMPRISING ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ACUTE RESPIRATORY DISEASE SYNDROME, PULMONARY HYPERSENSITIVITY, AND ALLERGIC RHINITIS IN A MAMMAL | PFIZER INC | 2002-04-30 | — | — | US | disclosed |
| CN-1254335-A | Nicotinamide derivatives | PFIZER PROD INC (US) | 2000-05-24 | — | — | CN | disclosed |
| EP-0971894-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Products Inc. (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998045268-A1 | NICOTINAMIDE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220249447-A1 | CF3-, OCF3-, SCF3-, and SF5-Containing Antibacterial Agents | SFXN3, CCR3, SF3A3 | DAO 3815/4885ERCC5 1342/4885FEN1 1725/4885 |
| US-20160280700-A1 | ANTIPARASITIC COMPOUNDS | TPP2, TPP1, SERPINB1 | DAO 345/4885ERCC5 4154/4885FEN1 2288/4885 |
| US-20170202849-A1 | ANTIPARASITIC COMPOUNDS | TPP2, TPP1, SERPINB1 | DAO 345/4885ERCC5 4154/4885FEN1 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.